Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Blood (2025) 146 (Supplement 1): 884.

https://doi.org/10.1182/blood-2025-884

Published: 2025

Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Blood (2025) 146 (Supplement 1): 466.

https://doi.org/10.1182/blood-2025-466

Published: 2025

Journal Articles

Intermediate‑dose cytarabine is noninferior to high‑dose cytarabine for AML consolidation: A systematic review and meta‑analysis

Flávia Xavier, Augusto Alves, João Victor da Cunha, Fernando de Oliveira, Vitor Monici, Abel Costa, Fernando Sergio Ferreira

Blood (2025) 146 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2025-1689

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Julio Chavez, Jason Westin, Javier Munoz, Emmanuel Bachy, Judit Jørgensen, Guilherme Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere De Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot

Blood (2025) 146 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2025-1006

Published: 2025

Journal Articles

Social determinants outweigh geographic barriers in Acute Myeloid Leukemia survival: Insights from a brazilian multicenter study

Luiza Perruso, Abel Costa, Wellington Silva, Rafaela Nalesso, Verena Pfister, Maria Daniela Colombo, Flávia Xavier, Renata Baptista, Fábio Pires, Ederson Mattos, Eduardo Rego

Blood (2025) 146 (Supplement 1): 965.

https://doi.org/10.1182/blood-2025-965

Published: 2025

Journal Articles

Clinical characteristics, treatment patterns, clinical outcomes and resource utilization in patients with chronic lymphocytic leukaemia (CLL): CREEK-Latin America subgroup analysis

Miguel Pavlovsky, Milton Lombana, Macarena Roa, Efreen Horacio Montaño Figueroa, Abel Costa, Rosanny Báez, Pushpalatha Kantharaju, Akemi Ishikawa, Luis Tejado-Gallegos, Ayman Elsayes

Blood (2025) 146 (Supplement 1): 4500.

https://doi.org/10.1182/blood-2025-4500

Published: 2025

Journal Articles

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

Blood (2025) 146 (Supplement 1): 5821.

https://doi.org/10.1182/blood-2025-5821

Published: 2025

Journal Articles

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

Samir Nabhan, Gabriel Cunha, Verena Pfister, Leila Perobelli, Erika Oshiro, Rodrigo Santucci, Milton Aranha, Talita Silveira, Jayr Schmidt Filho, Danielle De Farias, Cristiana Solza, Valeria Buccheri, Thiago Carneiro, Vera Figueiredo, Maura Colturato, Abel Costa, Fernanda Marques, Caio Cesar Justino, Celso Arrais-Rodrigues

Blood (2025) 146 (Supplement 1): 7413.

https://doi.org/10.1182/blood-2025-7413

Published: 2025

Journal Articles

Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine

Flávia Xavier, Fernando de Oliveira, Augusto Alves, João Victor da Cunha, Vitor Monici, Abel Costa, Nadia Cristina Misael

Blood (2025) 146 (Supplement 1): 8190.

https://doi.org/10.1182/blood-2025-8190

Published: 2025

Journal Articles

Low Rates of Documented Infection in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax + Hypomethylating Agents (VEN-HMA)

Abel Costa Neto, Renata Lyrio R Baptista, Mariana Guarana, Miguel Pedro de Queiroz Neto, Alessandra A. Johann, Vitor Augusto Mauad, Carlos Chiattone, Evandro Fagundes, Fernando Barroso, Elenaide Nunes, Melissa Dibai, Marcio Nucci

Blood (2024) 144 (Supplement 1): 7925.

https://doi.org/10.1182/blood-2024-202041

Published: 2024

Journal Articles

Use of Teclistamab Outside of Clinical Trials in Latin America: Risk of Infections and Immunoglobulin Replacement

Fernando Vieira Pericole, Edvan Crusoe, Glaciano Ribeiro, Juliana Lima, Erica Lammerhirt Ottoni, Rafael Cunha, Abel Costa, Priscilla Cury, James Maciel, Vania Hungria

Blood (2024) 144 (Supplement 1): 7847.

https://doi.org/10.1182/blood-2024-209492

Published: 2024

Journal Articles

Disparities in Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated in Public Versus Private Services in Brazil: Analysis of the Brazilian Acute Myeloid Leukemia Registry

Luiza Perruso, Abel Costa Neto, Wellington F. Silva, Marina Nascimento, Yana S Rabelo, Ederson Roberto Mattos, Fernanda R. Mendes, Juliana Martins, Verena Pfister, Maria Daniela Holthausen Perico, Carlos Chiattone, Eduardo M. Rego

Blood (2024) 144 (Supplement 1): 5181.

https://doi.org/10.1182/blood-2024-212321

Published: 2024

Journal Articles

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Verena Pfister, Fernanda de Morais Marques, Vinicius Campos de Molla, Flavia Parra, Mihoko Yamamoto, Rodrigo Santucci, Milton A. F. Aranha, Valeria Buccheri, Glaciano Ribeiro, Vera Figueiredo, Nelson Hamerschlak, Abel Costa Neto, Jayr Schmidt Filho, Talita Silveira, Adriana Scheliga, Matheus Vescovi Goncalves, Leila Perobelli, Carlos Chiattone, Celso Arrais-Rodrigues

Blood (2024) 144 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2024-210706

Published: 2024

Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2024-203131

Published: 2024

Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Blood (2023) 142 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2023-190590

Published: 2023

Journal Articles

Association of Sarcopenia with Toxicities and Survival after Autologous Hematopoietic Stem Cell Transplantation for Adults with Lymphomas

Abel Costa Neto, MD, Bruna Del Guerra Carvalho Moraes, Ilanna Marques Gomes Rocha, Felipe Acquesta Bezerra, MD, Galtieri Otavio Cunha Medeiros, Lucas Bassolli Oliveira Alves, Renata Ariza Marques Rossetti, PhD, Ana Paula Trussardi Fayh, PhD, Livia Caroline Barbosa Mariano, MD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2018-99-117717

Published: 2018

Journal Articles

FCGR2B B2.4 Haplotype Predicts Increased Risk of Red Blood Cell Alloimmunization in Sickle Cell Disease Patients

Abel Costa Neto, MD, Flávia Leite Santos, MD, Ingrid Helena Ribeiro, Valeria Brito Oliveira, Marcia Regina Dezan, Simone Kashima, PhD, Dimas Tadeu Covas, MD PhD, Alexandre Costa Pereira, MD PhD, Guilherme Henrique Hencklain Fonseca, MD, Frederico Moreira, José Eduardo Krieger, MD PhD, Sandra Fatima Menosi Gualandro, MD PhD, Vanderson Rocha, MD PhD, Alfredo Mendrone, Jr., MD PhD, Carla Luana Dinardo, MD PhD

Blood (2018) 132 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2018-99-113896

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Intermediate‑dose cytarabine is noninferior to high‑dose cytarabine for AML consolidation: A systematic review and meta‑analysis

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Social determinants outweigh geographic barriers in Acute Myeloid Leukemia survival: Insights from a brazilian multicenter study

Clinical characteristics, treatment patterns, clinical outcomes and resource utilization in patients with chronic lymphocytic leukaemia (CLL): CREEK-Latin America subgroup analysis

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine

Low Rates of Documented Infection in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax + Hypomethylating Agents (VEN-HMA)

Use of Teclistamab Outside of Clinical Trials in Latin America: Risk of Infections and Immunoglobulin Replacement

Disparities in Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated in Public Versus Private Services in Brazil: Analysis of the Brazilian Acute Myeloid Leukemia Registry

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Association of Sarcopenia with Toxicities and Survival after Autologous Hematopoietic Stem Cell Transplantation for Adults with Lymphomas

FCGR2B B2.4 Haplotype Predicts Increased Risk of Red Blood Cell Alloimmunization in Sickle Cell Disease Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only